Marico Q1 FY26 revenue rose 23.3%; profit up 8.2% (resurfacing an August move)

Resurfacing an August 2025 report: Marico posted Q1 FY26 revenue from operations of Rs 3,259 crore, led by 27.2% growth in India and 12.9% growth internationally. Net profit rose to Rs 513 crore. The company also increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60%.

— FiledTue, 22 Sept, 2026, 18:34 IST·First seen Tue, 22 Sept, 2026, 18:33 IST·Source Financial Express (via Wayback)

What happened

Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India revenue. The company raised its Plix maker Satiya

Key facts

  • Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income: Rs 3,315 crore, including Rs 56 crore other income
  • Total expenses: Rs 2,659 crore versus Rs 2,075 crore
  • India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
  • International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
  • India segment PBT: Rs 469 crore
  • International segment PBT: Rs 213 crore
  • Stake in Satiya Nutraceuticals increased to 60% on a fully diluted basis

Why this matters

Increasing its stake in Plix maker Satiya Nutraceuticals to 60% strengthens Marico’s position in health and wellness and signals deeper commitment to high-growth adjacent categories.

What to watch

  • Sequential India volume growth versus price-led growth in the next quarterly update.
  • Gross-margin trend and management commentary on copra, edible oil, packaging and currency costs.
  • Advertising-and-promotion spending as a percentage of sales.
  • Plix revenue growth, channel expansion, profitability and contribution after Marico raises its stake to 60%.
  • Growth in foods, premium personal care and digital-first portfolios relative to the core coconut-oil business.
  • International-market growth durability, especially currency-adjusted performance in Bangladesh, MENA and South Africa.
  • Expand Plix distribution beyond digital channels into general trade, modern trade and pharmacy-led health retail.
  • Increase cross-selling of wellness, nutrition and premium personal-care products through Marico's core distribution network.
  • Use selective price increases, pack-size changes and premiumisation to offset commodity-cost inflation while protecting volumes.
  • Step up advertising and digital marketing behind Saffola, Plix and other high-growth franchises.
  • Prioritize integration of Satiya Nutraceuticals while preserving its D2C brand positioning and growth autonomy.